Pricing Log in Create free account

Novogen Limited (KZIA) vs Neuraxis, Inc. (NRXS)

Novogen Limited and Neuraxis, Inc. are both Biotechnology companies. Novogen Limited and Neuraxis, Inc. are of similar size ($80.0M and $76.7M). Novogen Limited has the higher net margin (0.00% vs −159.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Novogen Limited leads on 8 and Neuraxis, Inc. on 4.

Valuation

Metric KZIA NRXS Biotechnology median
P/E n/m n/m 10.60
P/S — 14.39 9.40
P/B n/m 11.36 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 1.46 n/m 0.66
EV/Sales n/m 12.83 9.02
Earnings yield (2.99%) (12.36%) (32.88%)
Free cash flow yield 0.00% (7.56%) (23.13%)

Profitability

Metric KZIA NRXS Biotechnology median
Gross margin 0.00% 85.56% 68.51%
Operating margin — (144.51%) 0.00%
Net margin 0.00% (159.01%) 0.00%
Free cash flow margin 0.00% (106.10%) 0.00%
Return on equity 0.00% (153.96%) (51.96%)
Return on assets 0.00% (98.96%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KZIA NRXS Biotechnology median
Revenue growth (TTM) — 65.22% 6.76%
EPS growth (last fiscal year) 63.24% 22.13% 29.88%
Revenue growth, 5-year CAGR 11.56% 13.08% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KZIA NRXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.87 3.04 4.97
Net debt to EBITDA 0.30 0.64 1.01

Dividend

Metric KZIA NRXS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KZIA NRXS Biotechnology median
Market cap 80.01m 76.73m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack